Hong Kong stocks in the pharmaceutical sector rose, with Kairui Medicine increasing by over 6%.

On December 19, Gelonghui reported that Laika Medical rose over 6%, Galen Pharmaceutical increased by more than 2%, while Kato Pharmaceuticals and Shengnuo Medical followed suit.

Gelonghui FinanceDec 19 10:59

Laikai Pharmaceutical's self-developed PI3Kα inhibitor was selected for 2024 SABCS and has the best potential in its class

SHANGHAI, December 12, 2024 /PRNewswire/ -- Lai Kai Pharmaceutical (2105.HK) announced today that the company's self-developed result “a variant inhibitor targeting multiple types of PI3Kα mutants — pre-clinical study of LAE118” has been selected for the 2024 San Antonio Breast Cancer Symposium (SABCS) and will present relevant research in the form of a poster at a seminar in San Antonio, Texas, USA on December 13 data. “Very happy to come to Kay

PR NewswireDec 12 08:30

Hong Kong stock concept tracking | Eli Lilly and Co will invest 3 billion USD to expand its production base in the usa, as global demand for weight loss drugs exceeds supply (including concept stocks).

Eli Lilly and Co (LLY.US) will invest 3 billion dollars to expand its production base in the USA.

Zhitong FinanceDec 9 13:30

Hong Kong stocks fluctuated | Lai Kai Pharmaceutical-B (02105) surged over 7% in early trading, the Phase I clinical trial progress of LAE102 is going smoothly.

Lai Kai Pharmaceuticals-B (02105) rose more than 7% in the morning session, as of the time of writing, up 7.03%, at 14.3 Hong Kong dollars, with a turnover of 30.551 million Hong Kong dollars.

Zhitong FinanceDec 6 09:56

Hong Kong pharmaceutical stocks are weak.

GLEEDEC 4th | Lai Kai Medicine-B fell by 5.21%, Yi Ming Angke-B fell by 4.73%, Akeso fell by 3.47%, Remegen fell by 2.74%.

Gelonghui FinanceDec 4 09:46

Laekna Doses All Subjects in LAE102 Phase I Trial

MT NewswiresDec 4 08:24